MoonLake Immunotherapeutics Class Action Notice for Stock Purchasers
Written by Emily J. Thompson, Senior Investment Analyst
Source: Globenewswire
Updated: 5 day ago0mins
- Class Action Notice: Rosen Law Firm reminds investors who purchased MoonLake Immunotherapeutics (NASDAQ: MLTX) common stock between March 10, 2024, and September 29, 2025, to apply as lead plaintiffs by December 15, 2025, to participate in the class action and potentially receive compensation.
- Legal Fee Arrangement: Investors joining the class action will incur no out-of-pocket costs, as the law firm operates on a contingency fee basis, thereby reducing the financial burden on investors.
- Lawsuit Background: The lawsuit alleges that defendants made false and misleading statements during the class period, failing to disclose critical distinctions between Nanobodies and monoclonal antibodies, which led to investor losses when the truth emerged.
- Law Firm's Advantage: Rosen Law Firm specializes in securities class actions and has recovered over $438 million for investors in 2019 alone, demonstrating its successful track record and expertise in this field.
MLTX.O
$0.0000%Past 6 months
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
No Data
Powered By
Intellectia
Analyst Views on MLTX
Wall Street analysts forecast MLTX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MLTX is 15.38 USD with a low forecast of 5.00 USD and a high forecast of 30.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
16 Analyst Rating
9 Buy
5 Hold
2 Sell
Moderate Buy
Current: 14.995
Low
5.00
Averages
15.38
High
30.00
Current: 14.995
Low
5.00
Averages
15.38
High
30.00
Cantor Fitzgerald
Prakhar Agrawal
Overweight
maintain
2025-12-04
New
Reason
Cantor Fitzgerald
Prakhar Agrawal
Price Target
2025-12-04
New
maintain
Overweight
Reason
STAT reports that the FDA plans to shift toward requiring only one pivotal trial for approval rather than the traditional two, though details and timing remain unclear pending formal agency communication, Cantor Fitzgerald analyst Prakhar Agrawal tells investors in a research note. While the policy could have broad sector implications, it meaningfully boosts the likelihood of MoonLake's sonelokimab securing hidradenitis suppurativa approval based on a single positive pivotal study, the analyst says. Cantor has an Overweight rating on MoonLake shares.
H.C. Wainwright
H.C. Wainwright
Buy
downgrade
$30 -> $26
2025-11-21
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$30 -> $26
2025-11-21
downgrade
Buy
Reason
H.C. Wainwright lowered the firm's price target on MoonLake Immunotherapeutics to $26 from $30 and keeps a Buy rating on the shares. The firm cites the Q3 results and completed equity financing for the target drop.
Goldman Sachs
Neutral
maintain
$7 -> $8
2025-11-06
Reason
Goldman Sachs
Price Target
$7 -> $8
2025-11-06
maintain
Neutral
Reason
Goldman Sachs raised the firm's price target on MoonLake Immunotherapeutics to $8 from $7 and keeps a Neutral rating on the shares.
Oppenheimer
Oppenheimer
Outperform
maintain
$25 -> $30
2025-11-06
Reason
Oppenheimer
Oppenheimer
Price Target
$25 -> $30
2025-11-06
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on MoonLake Immunotherapeutics to $30 from $25 and keeps an Outperform rating on the shares. The firm notes MoonLake reported Q3 financials and provided a business update, including results from the Phase 2 LEDA study in palmo-plantar pustulosis, interim adolescent hidradenitis suppurativa data and interim long-term efficacy data from VELA-1/VELA-2.
See All Ratings
About MLTX
MoonLake Immunotherapeutics, formerly known as Helix Acquisition Corp, is a Switzerland-based company engaged in the healthcare industry. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The Company develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
About the author
Preview
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Sigh Up to Get Intellectia Insights
What are the main allegations against MoonLake in the class action lawsuit?
Why did MoonLake's stock price drop nearly 90% after trial results?
How might the lawsuit impact MoonLake's future stock performance?
Will MoonLake's drug sonelokimab face regulatory challenges after the trial failure?